Janssen-Cilag International NV (JNJ) Release: VOKANAMET® (Canagliflozin And Immediate Release Metformin Hydrochloride Fixed Dose Combination) Approved In The European Union For Treatment Of Adults With Type 2 Diabetes 
4/25/2014 9:51:08 AM
BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control. Canagliflozin as a single agent was approved as INVOKANA® in the European Union in November 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by